CPT 3750F Reimbursement & Policy Benchmarks

CPT code 3750F is a quality-reporting measure indicating that a provider did not administer corticosteroids at a dose ≥10 mg/day for 60 or more consecutive days in a patient with inflammatory bowel disease. Nationally, this code matters because prolonged corticosteroid exposure is linked to adverse outcomes and is a target for quality improvement in gastroenterology care. Tracking avoidance of extended corticosteroid use supports safer long-term management strategies and value-based care goals.

The analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise explanation of the clinical context for the measure, how it maps to outpatient and specialty ambulatory settings, and what the code signifies for quality reporting. The publication summarizes common billing considerations, available modifiers, and how the code is used alongside diagnosis and service documentation. It also outlines typical benchmarks and policy implications for payer coverage and performance measurement where available. This summary provides clinicians, billing staff, and policy analysts with the operational context needed to interpret CPT code 3750F in national reporting and claims workflows.

Billing Code Overview

CPT code 3750F documents that the provider does not administer corticosteroid medication at a dose greater than or equal to 10 mg per day for 60 or more consecutive days in a patient with inflammatory bowel disease. This measure captures corticosteroid exposure over a sustained period and is typically used in quality reporting and clinical monitoring of long-term steroid use.

Service type: Quality measure / medication exposure documentation
Typical site of service: Ambulatory clinic, specialty gastroenterology office, or outpatient infusion clinic where ongoing medication management and chronic-disease monitoring occur.

Clinical Context

A 28-year-old patient with a history of moderate-to-severe Crohn disease presents for routine follow-up in a gastroenterology clinic. The patient reports multiple prior exacerbations treated with oral corticosteroids. Current management focuses on steroid-sparing strategies with immunomodulators and biologic therapy; the provider documents that the patient has not been prescribed systemic corticosteroids at a dose ≥10 mg prednisone equivalent per day for 60 or more consecutive days. The clinical workflow: evaluation of symptoms and medication history, review of steroid exposure timeline, documentation of steroid-sparing therapy plan, coordination with pharmacy for biologic or immunomodulator refills, and routine follow-up visits to monitor disease activity and adverse effects. Typical site of service is an outpatient gastroenterology clinic or infusion center when biologic therapy is administered.

Coding Specifications

Modifier	Description	When to Use
`52`	Reduced services	Use when the service related to documentation or visit is partially reduced in scope compared with typical expectations for the encounter.
`53`	Discontinued procedure	Use when the encounter or planned procedure is started but discontinued prior to completion for patient or clinical reasons.

Taxonomy Code	Specialty	Notes
207RG0100X	Gastroenterology	Gastroenterologists manage inflammatory bowel disease and make steroid use decisions.
207RT0006X	Pediatric Gastroenterology	For pediatric patients with IBD and steroid exposure monitoring.
208000000X	Internal Medicine	Internists frequently manage chronic IBD and coordinate steroid-sparing care.
207RH0000X	Colorectal Surgery	Surgeons involved when disease complications require surgical intervention and perioperative steroid considerations.
186L00000X	Pharmacy	Clinical pharmacists assist with biologic/immunomodulator dosing and steroid taper instructions.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`K50.90`	Crohn disease, unspecified, without complication	Crohn disease is a primary inflammatory bowel disease where long-term systemic corticosteroid avoidance is recommended.
`K51.90`	Ulcerative colitis, unspecified, without complication	Ulcerative colitis management includes minimizing prolonged steroid exposure and documenting steroid use status.
`K50.811`	Crohn disease, of small intestine, with intestinal obstruction	Complicated IBD may alter steroid use and necessitate careful documentation of systemic corticosteroid exposure.
`K50.919`	Crohn disease, unspecified, with unspecified complication	Complications influence treatment choices and monitoring of corticosteroid exposure.
`K51.811`	Ulcerative (chronic) pancolitis	Extensive colitis often requires steroid-sparing maintenance therapies; documentation of steroid duration is essential.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	Common visit code used to document the provider encounter where steroid history and management plan are reviewed.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used when the visit requires moderate complexity decision-making about steroid-sparing therapy and monitoring.
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used when initiating infusion-based biologic therapy as a steroid-sparing treatment.
`J1745`	Injection, infliximab, 10 mg (HCPCS Level II)	Biologic commonly administered as an alternative to prolonged systemic corticosteroids.
`99406`	Smoking and tobacco use cessation counseling visit, intermediate, greater than 3 minutes up to 10 minutes	Ancillary counseling code sometimes used in chronic disease management visits addressing modifiable risks (listed as an example of ancillary services).

OpenPayer

Summary & Overview

CPT 3750F: No Prolonged Corticosteroid Use in Inflammatory Bowel Disease